Brokerages expect that AzurRx BioPharma Inc (NASDAQ:AZRX) will announce earnings of ($0.15) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for AzurRx BioPharma’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.21). AzurRx BioPharma also reported earnings per share of ($0.15) in the same quarter last year. The firm is expected to announce its next quarterly earnings results on Friday, November 15th.

According to Zacks, analysts expect that AzurRx BioPharma will report full-year earnings of ($0.76) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.69). For the next year, analysts anticipate that the firm will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.67) to ($0.41). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow AzurRx BioPharma.

AzurRx BioPharma (NASDAQ:AZRX) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03).

A number of research firms have weighed in on AZRX. Maxim Group set a $3.00 target price on AzurRx BioPharma and gave the stock a “buy” rating in a report on Tuesday, October 15th. HC Wainwright set a $5.00 target price on AzurRx BioPharma and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, ValuEngine upgraded AzurRx BioPharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Six analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $7.10.

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of AzurRx BioPharma by 57.6% during the 2nd quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock worth $72,000 after acquiring an additional 15,463 shares during the period. Royal Bank of Canada purchased a new position in shares of AzurRx BioPharma during the 2nd quarter worth approximately $48,000. JPMorgan Chase & Co. purchased a new position in shares of AzurRx BioPharma during the 2nd quarter worth approximately $57,000. Finally, Vanguard Group Inc. grew its holdings in shares of AzurRx BioPharma by 255.0% during the 2nd quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock worth $443,000 after acquiring an additional 186,985 shares during the period. Hedge funds and other institutional investors own 12.11% of the company’s stock.

Shares of AZRX stock traded up $0.16 during midday trading on Monday, reaching $0.77. 708,300 shares of the stock were exchanged, compared to its average volume of 192,677. AzurRx BioPharma has a 1 year low of $0.42 and a 1 year high of $3.10. The company’s 50 day moving average is $0.65 and its two-hundred day moving average is $1.33. The firm has a market cap of $17.36 million, a PE ratio of -0.88 and a beta of 2.12.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Featured Story: Balance Sheet

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.